Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-01797, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV TramadolThe FDA Has Not Provided a Decision Regarding the NDA - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and.
Why Fortress Biotech Stock Is Sinking Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace